CV-IC-03 · standards
Dual-natured. The permissibility problem is that citing a disease-population study evidences intended use, and that problem exists however good the study is.
Found on 7 of the 1,524 best-selling listings we have ruled, 8 times in total. That is 7 live product pages carrying this wording today.
FTC Health Products Compliance Guidance (December 2022)
“health-benefit claims generally require randomised, controlled human clinical testing; this is the document Walmart's substantiation checklist is asking about”
Source checked 2026-08-18.
“the criteria by which FDA determines that a statement is a disease claim rather than a structure/function claim”
Source checked 2026-08-18.
FDCA s.201(g)(1)(B), 21 U.S.C. 321(g)(1)(B)
“definition of 'drug': articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease”
Source checked 2026-08-18.
An interpretation. We applied a published legal test to the published copy and reached a conclusion. Reasonable reviewers applying the same test can disagree at the margin; this is our reviewer's professional opinion, and the test is cited so you can check the reasoning.
Claims Verified, standard CV-IC-03 "Ingredient study on a disease population", standards v1.3.1, retrieved 16 September 2026, https://claimsverified.org/standards/CV-IC-03/
Or put it in your own policy
Marketing copy must not use "Ingredient study on a disease population" or equivalent wording. See Claims Verified standard CV-IC-03 (standards v1.3.1): https://claimsverified.org/standards/CV-IC-03/
Cite it freely with attribution and the version. The whole register is machine-readable at /standards/registry.json. Rulings are our published professional opinion, not legal advice.
All 98 standards and the 98 in force · Check a listing against them free